{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:40Z","timestamp":1786991200255,"version":"build-2736575974"},"reference-count":178,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jaad.2014.07.032","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T18:08:54Z","timestamp":1421086134000},"page":"203-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Cutaneous adverse effects of targeted therapies"],"prefix":"10.1016","volume":"72","author":[{"given":"James B.","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren E.","family":"Golitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.07.032_bib1","first-page":"1462","article-title":"Dermatologic challenges in cancer patients and survivors","volume":"21","author":"Agha","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2014.07.032_bib2","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaad.2014.07.032_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections\u00a0in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2014.07.032_bib4","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","article-title":"The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies","volume":"65","author":"Balagula","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archdermatol.2011.719","article-title":"Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents","volume":"147","author":"Borovicka","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib11","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.2174\/092986706779026174","article-title":"Targeting the EGFR pathway for cancer therapy","volume":"13","author":"Johnston","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaad.2014.07.032_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib14","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.jaad.2014.07.032_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","article-title":"Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors","volume":"40","author":"Brodell","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2014.07.032_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1523-1747.ep12276708","article-title":"Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition","volume":"85","author":"Green","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcp.21585","article-title":"Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?","volume":"218","author":"Rodeck","year":"2009","journal-title":"J Cell Physiol"},{"issue":"11 suppl 12","key":"10.1016\/j.jaad.2014.07.032_bib18","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"P\u00e9rez-Soler","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2014.07.032_bib19","doi-asserted-by":"crossref","first-page":"e39706","DOI":"10.1371\/journal.pone.0039706","article-title":"Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor","volume":"7","author":"Bangsgaard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2014.07.032_bib20","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-11-0545","article-title":"The phosphatase inhibitor\u00a0menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab","volume":"17","author":"Perez-Soler","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2014.07.032_bib21","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib23","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2014.07.032_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","article-title":"Skin toxicities of targeted therapies","volume":"45","author":"Segaert","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side\u00a0effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Ro\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0781.2007.00273.x","article-title":"Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib","volume":"23","author":"Luu","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2014.07.032_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1634\/theoncologist.2010-0082","article-title":"Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)","volume":"15","author":"Jatoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2014.07.032_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/annonc\/mdl409","article-title":"Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients","volume":"18","author":"Bossi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib31","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","article-title":"An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors","volume":"64","author":"Amador","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.032_bib32","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/bjc.2012.482","article-title":"Association of creatine kinase and skin toxicity in phase I trials of anticancer agents","volume":"107","author":"Moreno Garcia","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib33","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the\u00a0response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2014.07.032_bib34","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mds141","article-title":"Daily skin care habits and the risk of skin eruptions and symptoms in cancer patients","volume":"23","author":"Byun","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dth.12027","article-title":"Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4","volume":"26","author":"Fischer","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.07.032_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib37","first-page":"236","article-title":"The SERIES clinic:\u00a0an interdisciplinary approach to the management of\u00a0toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib38","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib39","first-page":"1601","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2340\/00015555-0330","article-title":"Cetuximab-induced acneiform eruption and the response to isotretinoin","volume":"88","author":"Vezzoli","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib43","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/JTO.0b013e3181ec1729","article-title":"Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer","volume":"5","author":"Bidoli","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11 suppl 5","key":"10.1016\/j.jaad.2014.07.032_bib46","first-page":"22","article-title":"Clinical management of EGFRI dermatologic toxicities: the European perspective","volume":"21","author":"Segaert","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2014.07.032_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"363","author":"Vincenzi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1013027","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Gerber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib49","doi-asserted-by":"crossref","unstructured":"Zheng S, Pan YL, Wang JL, et al. Gefitinib-induced hair alterations. BMJ Case Rep. doi: http:\/\/dx.doi.org\/10.1136\/bcr.09.2008.0878. Published online March 17, 2009.","DOI":"10.1136\/bcr.09.2008.0878"},{"key":"10.1016\/j.jaad.2014.07.032_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11531920-000000000-00000","article-title":"Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors","volume":"12","author":"Cohen","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib51","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1200\/JCO.2011.34.6858","article-title":"Trichomegaly and poliosis of the\u00a0eyelashes during cetuximab treatment of metastatic colorectal cancer","volume":"29","author":"Rodriguez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1590\/S0365-05962010000600025","article-title":"Blepharitis and trichomegaly induced by cetuximab","volume":"85","author":"Criado","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/DER.0b013e31826e45d7","article-title":"Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases","volume":"23","author":"Fabbrocini","year":"2012","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2014.07.032_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/15569527.2011.636118","article-title":"Trichomegaly and other external eye side effects associated with epidermal growth factor","volume":"31","author":"Fraunfelder","year":"2012","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jaad.2014.07.032_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3747\/co.v18i3.762","article-title":"Eyelash trichomegaly secondary to panitumumab therapy","volume":"18","author":"Morris","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib56","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.4065\/mcp.2011.0356","article-title":"Epidermal growth factor receptor-induced hirsutism and trichomegaly","volume":"86","author":"Munoz","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2014.07.032_bib57","first-page":"439","article-title":"Eye complications of cetuximab therapy","volume":"16","author":"Melichar","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jaad.2014.07.032_bib58","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839)","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib59","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","article-title":"A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"36","author":"Pongpudpunth","year":"2009","journal-title":"J Cutan Pathol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2014.07.032_bib60","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","article-title":"A case of cicatricial alopecia associated with erlotinib","volume":"23","author":"Yang","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib62","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib64","first-page":"1656","article-title":"Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody","volume":"142","author":"Kerob","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-4632.2011.05082.x","article-title":"The\u00a0management of EGFR inhibitor adverse events: a case series and treatment paradigm","volume":"51","author":"Wnorowski","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib67","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archdermatol.2012.3022","article-title":"Gefitinib-induced paronychia: response to autologous platelet-rich plasma","volume":"148","author":"Kwon","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/carcin\/bgi220","article-title":"Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor","volume":"27","author":"El-Abaseri","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jaad.2014.07.032_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1562\/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2","article-title":"UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival","volume":"72","author":"Peus","year":"2000","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.jaad.2014.07.032_bib70","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-12-438","article-title":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during\u00a0first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study","volume":"12","author":"Thaler","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib71","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib72","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1345\/aph.1E127","article-title":"Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors","volume":"39","author":"Severino","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2014.07.032_bib74","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib77","first-page":"509","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib78","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib79","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-4632.2006.02930.x","article-title":"Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia","volume":"45","author":"Kuwano","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib80","first-page":"465","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"issue":"2 suppl 2","key":"10.1016\/j.jaad.2014.07.032_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment: specific issues related to safety, fertility","volume":"40","author":"Hensley","year":"2003","journal-title":"pregnancy. Semin Hematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib82","first-page":"125","article-title":"The kit-ligand (steel\u00a0factor) and its receptor c-kit\/W: pleiotropic roles in gametogenesis and melanogenesis","author":"Besmer","year":"1993","journal-title":"Dev Suppl"},{"key":"10.1016\/j.jaad.2014.07.032_bib83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.2006.07359.x","article-title":"Imatinib mesilate inhibits melanogenesis in vitro","volume":"155","author":"Cario-Andr\u00e9","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib84","first-page":"215","article-title":"Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors","volume":"2","author":"Huang","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaad.2014.07.032_bib85","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2013.75","article-title":"Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia","volume":"149","author":"Samimi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.07.032_bib87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2133.2005.06813.x","article-title":"Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?","volume":"153","author":"Legros","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib88","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2340\/00015555-0636","article-title":"Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia","volume":"89","author":"Kawakami","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555-0758","article-title":"Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature","volume":"90","author":"Kuraishi","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0781.2011.00621.x","article-title":"Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate","volume":"28","author":"Brazzelli","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2014.07.032_bib91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09546630410015556","article-title":"Oral lichenoid eruption secondary to imatinib (Glivec)","volume":"15","author":"Ena","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2014.07.032_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000063899","article-title":"Oral lichenoid reaction to imatinib (STI 571, Gleevec)","volume":"205","author":"Lim","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.07.032_bib93","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1365-4632.2006.03171.x","article-title":"Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases","volume":"45","author":"Pascual","year":"2006","journal-title":"Int J Dermatol"},{"issue":"6-7 pt 1","key":"10.1016\/j.jaad.2014.07.032_bib94","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0151-9638(04)93669-1","article-title":"Lichenoid cutaneous reaction to imatinib [in French]","volume":"131","author":"Roux","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib95","first-page":"14","article-title":"Oral and cutaneous lichenoid\u00a0reaction with nail changes secondary to imatinib: report of a case and literature review","volume":"14","author":"Wahiduzzaman","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2014.07.032_bib96","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2230.2009.03250.x","article-title":"Imatinib: a designer drug, another cutaneous complication","volume":"34","author":"Dickens","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib97","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2014.07.032_bib98","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.jaad.2004.10.888","article-title":"Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases","volume":"53","author":"Brazzelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib99","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000063900","article-title":"Pityriasis rosea associated with imatinib (STI571, Gleevec)","volume":"205","author":"Konstantopoulos","year":"2002","journal-title":"Dermatology"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2014.07.032_bib100","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.5021\/ad.2011.23.S3.S360","article-title":"Pityriasis rosea-like drug eruption induced by imatinib mesylate (Gleevec)","volume":"23","author":"Cho","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000051705","article-title":"Acute\u00a0generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia","volume":"203","author":"Brouard","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.07.032_bib102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000088510","article-title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia","volume":"211","author":"Gambillara","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.07.032_bib103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0609.2002.02830.x","article-title":"Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia","volume":"69","author":"Schwarz","year":"2002","journal-title":"Eur J Haematol"},{"issue":"8-9 pt 1","key":"10.1016\/j.jaad.2014.07.032_bib104","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0151-9638(06)70992-9","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy [in French]","volume":"133","author":"Le Nouail","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00277-007-0265-y","article-title":"Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose","volume":"86","author":"Mahapatra","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib106","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archderm.144.3.361","article-title":"Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic\u00a0myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells","volume":"144","author":"Kaune","year":"2008","journal-title":"Arch Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2014.07.032_bib108","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2014.07.032_bib109","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2141.2003.04208_3.x","article-title":"Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate","volume":"120","author":"Rousselot","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.0303-6987.2003.053.x","article-title":"Mycosis fungoides-like reaction in a patient treated with Gleevec","volume":"30","author":"Clark","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2014.07.032_bib111","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.leu.2403115","article-title":"Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia","volume":"18","author":"Breccia","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2014.07.032_bib112","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2003.04277.x","article-title":"Precipitation of porphyria cutanea tarda by imatinib mesylate?","volume":"121","author":"Ho","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib113","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2003.04151_4.x","article-title":"A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib\u00a0mesylate (STI 571, Glivec)","volume":"120","author":"Drummond","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.annder.2010.11.009","article-title":"Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib [in French]","volume":"138","author":"de Masson","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/DAD.0b013e31828cf3b7","article-title":"Perforating folliculitis in a patient\u00a0treated with nilotinib: a further evidence of C-kit involvement","volume":"36","author":"Llamas-Velasco","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2014.07.032_bib116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000073102","article-title":"Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign","volume":"207","author":"Banka","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.07.032_bib117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1440-0960.2007.00384.x","article-title":"Imatinib-induced erythroderma","volume":"48","author":"Mathew","year":"2007","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib118","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2340\/00015555-0015","article-title":"Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia","volume":"86","author":"Oztas","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0378-6323.77471","article-title":"Exfoliative dermatitis with leukemia cutis in a patient with chronic myeloid leukemia: a rare association","volume":"77","author":"Raj","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2014.07.032_bib120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0378-6323.95491","article-title":"Imatinib mesylate induced erythroderma","volume":"78","author":"Sanghavi","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2014.07.032_bib121","first-page":"538","article-title":"Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism","volume":"17","author":"Vano-Galvan","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib122","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamadermatol.2013.1375","article-title":"A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib","volume":"149","author":"Hansen","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib123","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2006.01.038","article-title":"Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy","volume":"54","author":"Markham","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib124","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2014.07.032_bib125","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","article-title":"ALK1 as an emerging target for antiangiogenic therapy of cancer","volume":"117","author":"Cunha","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2014.07.032_bib126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2008.07.121","article-title":"VEGF receptor protein-tyrosine kinases: structure and regulation","volume":"375","author":"Roskoski","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaad.2014.07.032_bib127","first-page":"243","article-title":"Cutaneous side effects of inhibition of VEGF signal transduction","volume":"8","author":"Wozel","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.07.032_bib128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that\u00a0target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jamcollsurg.2011.12.030","article-title":"Bevacizumab-associated fistula formation in postoperative colorectal cancer patients","volume":"214","author":"Ganapathi","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jaad.2014.07.032_bib130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib131","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2011.11.021","article-title":"Safety of bevacizumab in metastatic breast cancer patients undergoing surgery","volume":"48","author":"Cort\u00e9s","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib132","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib133","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.2009.22.0541","article-title":"Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer","volume":"27","author":"Blumenschein","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib134","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib135","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib136","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib137","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib138","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2007.11.1047","article-title":"Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group","volume":"25","author":"Ryan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib139","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.07.032_bib140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib141","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib142","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2014.07.032_bib143","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.07.032_bib144","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2014.07.032_bib146","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/2013.jamadermatol.192","article-title":"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib","volume":"148","author":"Giacchero","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib147","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib148","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in\u00a0patients treated with sorafenib: a clinicopathological study\u00a0of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib149","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1592\/phco.30.1.52","article-title":"Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction","volume":"30","author":"Jain","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2014.07.032_bib150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14740330903510608","article-title":"Toxicity of sorafenib: clinical and molecular aspects","volume":"9","author":"Blanchet","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2014.07.032_bib151","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","article-title":"Placebo-controlled trial to\u00a0determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5","volume":"28","author":"Wolf","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib152","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib153","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2014.07.032_bib154","first-page":"1331","article-title":"Chloracne-like drug eruption associated with sorafenib","volume":"10","author":"Pickert","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib155","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2006.10.981","article-title":"Sorafenib-induced erythema multiforme","volume":"56","author":"MacGregor","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib156","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2009.02.004","article-title":"Array of cutaneous adverse effects associated with sorafenib","volume":"61","author":"Kong","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib157","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib158","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib159","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","article-title":"Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition","volume":"144","author":"Hartmann","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib160","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","article-title":"Tyrosine kinase inhibition and grey hair","volume":"361","author":"Robert","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.07.032_bib161","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in\u00a0patients treated with the multitargeted kinase inhibitors\u00a0sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib162","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib163","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMc0802736","article-title":"Scrotal cutaneous side effects of sunitinib","volume":"359","author":"Billemont","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.07.032_bib164","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib165","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib166","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/SPC.0b013e32832e4681","article-title":"Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma","volume":"3","author":"Guevremont","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jaad.2014.07.032_bib167","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/2047-783X-16-11-491","article-title":"Sunitinib induced pyoderma gangrenosum-like ulcerations","volume":"16","author":"Akanay-Diesel","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jaad.2014.07.032_bib168","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"Eruptive nevi associated with sorafenib treatment [in French]","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib169","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib170","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamadermatol.2013.263","article-title":"Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib","volume":"149","author":"Jim\u00e9nez-Gallo","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib171","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.07.032_bib172","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2014.07.032_bib173","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annder.2009.09.010","article-title":"Sorafenib-induced multiple eruptive keratoacanthomas [in French]","volume":"136","author":"Jantzem","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.07.032_bib174","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib175","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib176","first-page":"308","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib","volume":"10","author":"Lynch","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.07.032_bib177","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327480901600110","article-title":"Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene","volume":"16","author":"Marquez","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.jaad.2014.07.032_bib178","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith","year":"2009","journal-title":"Dermatol Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214017630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214017630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:19Z","timestamp":1759271599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214017630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":178,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0190962214017630"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse effects of targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(14)02282-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}